Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | HRH2 | P25021 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.30 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.30 |
| ▸ | MC5R | P33032 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336658 | 1.00 | ALOX5 (0.36) | ALOX5KMT2AHRH2F2PLG | |
| SCHEMBL4697600 | 0.77 | ALOX5 (0.32) | ALOX5 | |
| SCHEMBL3337061 | 0.77 | TPSAB1 (0.56) | ALOX5PRSS1HTTTPSAB1TPSD1 | |
| SCHEMBL3336645 | 0.75 | HPGD (0.40) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL10345824 | 0.64 | CTRB1 (0.40) | — | |
| SCHEMBL5429609 | 0.63 | KEAP1 (0.55) | L3MBTL1HTT | |
| SCHEMBL5430592 | 0.62 | HDAC2 (0.53) | HRH2HRH4HRH3HTT | |
| SCHEMBL10854943 | 0.60 | ALDH1A1 (0.45) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL27709640 | 0.58 | ALDH1A1 (0.46) | KMT2AL3MBTL1HTT | |
| SCHEMBL14219241 | 0.57 | ALDH1A1 (0.56) | ALOX5KMT2AL3MBTL1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1871741-A2 | SUBSTITUTED AZETIDINONES | Daiamed, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | ALOX5 742/4885KMT2A 1432/4885HRH2 122/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | ALOX5 742/4885KMT2A 1432/4885HRH2 122/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | ALOX5 742/4885KMT2A 1432/4885HRH2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.